2023
DOI: 10.3390/pharmaceutics15030882
|View full text |Cite
|
Sign up to set email alerts
|

Use of In Vitro Dynamic Colon Model (DCM) to Inform a Physiologically Based Biopharmaceutic Model (PBBM) to Predict the In Vivo Performance of a Modified-Release Formulation of Theophylline

Abstract: A physiologically based biopharmaceutic model (PBBM) of a modified-release formulation of theophylline (Uniphyllin Continus® 200 mg tablet) was developed and implemented to predict the pharmacokinetic (PK) data of healthy male volunteers by integrating dissolution profiles measured in a biorelevant in vitro model: the Dynamic Colon Model (DCM). The superiority of the DCM over the United States Pharmacopeia (USP) Apparatus II (USP II) was demonstrated by the superior predictions for the 200 mg tablet (average a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 41 publications
0
1
0
Order By: Relevance
“…The average absolute fold error (AAFE) was calculated, as described elsewhere [ 21 , 22 , 23 ], to assess the overall predictive accuracy of the model. The average fold error (AFE) was calculated, as described elsewhere [ 24 ], to assess the tendency for over- or underprediction of the model as well as predicted/observed ratio.…”
Section: Methodsmentioning
confidence: 99%
“…The average absolute fold error (AAFE) was calculated, as described elsewhere [ 21 , 22 , 23 ], to assess the overall predictive accuracy of the model. The average fold error (AFE) was calculated, as described elsewhere [ 24 ], to assess the tendency for over- or underprediction of the model as well as predicted/observed ratio.…”
Section: Methodsmentioning
confidence: 99%